Key Points
- To evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RA) on major adverse cardiovascular events (MACE), all-cause mortality, and cardiovascular risk factors in patients with type 2 diabetes.
- Meta-analysis of 37 randomized clinical trials with durations of at least 6 months comparing GLP-1 RA therapy to non-GLP-1 RA comparators in type 2 diabetes.
- Calculated Mantel–Haenszel odds ratios (MH-OR) for MACE and mortality, alongside endpoint assessments of systolic/diastolic blood pressure, total cholesterol, HDL cholesterol, and triglycerides.
- Across 33 trials reporting MACE data (25 with at least one event), GLP-1 RA did not show a statistically significant reduction in MACE overall compared to all control therapies combined [MH-OR 0.78 (95% CI 0.54–1.13), p = 0.18].
- Subgroup analyses revealed a statistically significant reduction in MACE incidence with GLP-1 RA when compared specifically to placebo and pioglitazone, as well as a non-significant reduction trend versus DPP-4 inhibitors.
- GLP-1 RA therapy exhibited no significant effect on overall mortality across pooled trials, though a non-significant favorable trend was observed relative to placebo.
Structured PICO
Does GLP-1 RA reduce major cardiovascular events and mortality in patients with type 2 diabetes?
PPopulationPatients with type 2 diabetes from 37 randomized clinical trials (duration ≥6 months)
IInterventionGlucagon-like peptide-1 receptor agonists (GLP-1 RA)
CComparatorNon-GLP-1 RA agent (including placebo, pioglitazone, DPP4i)
OOutcomeMajor cardiovascular events (MACE) and mortalitycomposite
This meta-analysis confirms the short-term cardiovascular safety of GLP-1 RAs in low-risk individuals with type 2 diabetes, though the reduction in MACE was not statistically significant overall.